Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
SAINT LAURENT, Quebec, May 03, 2018 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2018 financial results after market close on May 10, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, May 10, 2018
Time: 4:30 p.m. ET
Conference dial-in: (833) 231-8269
International dial-in: (647) 689-4114
Conference ID: 2398086
Webcast Registration: Click here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 [email protected] Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 [email protected]
